The US Food and Drug Administration (FDA) has announced seven new clinical trial grants awarded under the Orphan Products Grants Program for clinical trials to address the unmet needs of people affected by rare diseases. In total, clinical researchers will receive approximately $17.2 million over the next four years. Newly funded projects: Palvella Therapeutics received […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!